The Medicines and Healthcare products Regulatory Agency announced Friday that it approved a maximum dose of up to 7.2mg per week of semaglutide, or Wegovy, on January 6. It is administered as 3 injections of 2.4 mg for weight management in adult patients with obesity only, in addition to a reduced-calorie diet and exercise, who have a Body Mass Index of 30kg/m2 or higher. This does not apply to overweight patients with a BMI of less than 30kg/m2 using Wegovy for weight management or for patients using Wegovy to lower their risk of serious heart problems. Wegovy is made by Novo Nordisk (NVO).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Stock (NVO) Jumps as UK Clears Higher Wegovy Dose
- Eli Lilly Stock (LLY) Falls 5% After FDA Delays Decision on Weight-Loss Pill
- Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher
- Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports
- Why GLP-1 Weight-Loss Pills Might Be Great News for Airline Stocks